Core Viewpoint - The company, 荃信生物-B, has announced a share placement agreement to issue 5 million shares at a price of HKD 20.0 per share, which represents a discount of approximately 10.95% compared to the last trading price of HKD 22.46 on August 15, 2025 [1][2] Group 1 - The placement shares will account for approximately 2.25% of the existing shares as of the announcement date and about 2.20% of the expanded share capital after the placement [1] - The expected net proceeds from the placement, after deducting related costs, will be approximately HKD 99 million [2] - The company plans to allocate around 60% of the net proceeds to repay existing interest-bearing bank loans, which have increased due to additional borrowings for R&D expenses [2] Group 2 - Approximately 30% of the net proceeds will be used for the development of new pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be allocated for working capital and other corporate purposes [2]

Core Viewpoint - The company, Qianxin Biotechnology-B (02509.HK), has announced a placement agreement to issue 5 million shares at a price of HKD 20.0 per share, which represents a discount of approximately 10.95% from the market price on August 15 [1][2] Group 1 - The placement shares represent approximately 2.25% of the total issued shares as of the announcement date and about 2.20% of the total issued shares after the placement [1] - The placement is being conducted by CICC as the placement agent, with the sole subscriber being TruMed Health Innovation Fund LP, a Cayman Islands registered exempt limited partnership focused on healthcare stocks [1] - The expected total proceeds from the placement are approximately HKD 100 million, with a net amount of about HKD 99 million after expenses [2] Group 2 - Approximately 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowing for R&D expenses, thereby improving the company's financial position [2] - About 30% of the net proceeds will be allocated for the development of new product pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be used for working capital and other corporate purposes [2]

Group 1 - Company announced a placement agreement to issue 5 million shares at a price of HKD 20.0 per share, representing approximately 2.25% of the existing shares as of the announcement date [1] - The placement price of HKD 20.0 is a discount of about 10.95% compared to the last closing price of HKD 22.46 on August 15, 2025 [1] Group 2 - The expected net proceeds from the placement, after deducting related costs, will be approximately HKD 99 million [2] - About 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowings for R&D expenses, thereby improving the company's financial position [2] - Approximately 30% of the net proceeds will be allocated for the development of new pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be used for working capital and other corporate purposes [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考，並不構成收購、購買或認購本公司任何證券之邀請或要約。 本 公 告 不 得 直 接 或 間 接 在 美 國 境 內 或 向 美 國 境 內 分 發。本 公 告 不 構 成 或 組 成 在 美 國 購 買 或 認 購 證 券 之 任 何 要 約 或 招 攬 之 一 部 分。本 公 告 提 及 之 本 公 司 股 份 未 曾 且 將不會根據1933年 美 國 證 券 法（經 修 訂）（「證券法」）或 向 美 國 任 何 州 或 其 他 司 法 管 轄區之任何證券監管機構註冊，且不得直接或間接向美國或在美國境內發售、出售、 轉售、質押、轉讓或交付，惟依據證券法註冊或豁免註冊規定者除外。本公告提及 之本公司股份乃依據證券法S規 例 於 美 國 境 外 以 離 岸 交 易 方 式 發 售 及 出 售。本 公 司股份將不會在美國公開發售。 Q ...

Core Insights - The company reported a revenue of RMB 206 million for the six months ending June 30, 2025, representing a year-on-year increase of 359.69% [1] - Research and development (R&D) expenses amounted to RMB 151 million, reflecting a year-on-year increase of 4.25% [1] - The net loss for the period was RMB 30.93 million, a significant reduction of 83.11% compared to the previous year [1] - The loss per share was RMB 0.13 [1] Revenue Breakdown - The revenue of RMB 206 million primarily included income from licensing agreements, which accounted for RMB 181 million, derived from upfront payments related to the overseas licensing of QX030N and a non-cash consideration for approximately 24.88% equity in Caldera Therapeutics, Inc., as well as milestone fees from the Phase III trial of QX004N [1] - Additionally, revenue from CDMO services and R&D services for projects QX004N and QX008N contributed approximately RMB 22 million [1] R&D Expenses Analysis - R&D expenses increased from RMB 145 million for the six months ending June 30, 2024, to RMB 151 million for the same period in 2025, marking a rise of 4.25% [1] - The increase in R&D spending was primarily due to higher clinical trial costs associated with the advancement of the company's clinical trials, despite a reduction of RMB 5.87 million in equity-settled share-based payment amortization [1]

本文源自：金融界AI电报 荃信生物-B(02509.HK)发布截至2025年6月30日止6个月业绩，该集团取得收入人民币2.06亿元(单位下 同)，同比增加359.69%;研发开支1.51亿元，同比增加4.25%;期内亏损3093.3万元，同比减少83.11%;每股 亏损0.13元。 ...

Group 1 - The company reported a revenue of RMB 206 million for the six months ending June 30, 2025, representing a year-on-year increase of 359.69% [1] - Research and development (R&D) expenses increased by 4.25% to RMB 151 million compared to RMB 145 million for the same period last year [1] - The net loss for the period was RMB 30.93 million, a significant reduction of 83.11% year-on-year, with a loss per share of RMB 0.13 [1] Group 2 - Revenue primarily came from licensing agreements, including upfront payments related to the overseas licensing of QX030N and a non-cash consideration for approximately 24.88% equity in Caldera Therapeutics, Inc., totaling RMB 181 million [1] - Additional revenue was generated from CDMO services and R&D services for projects QX004N and QX008N, amounting to approximately RMB 22 million [1] - The increase in R&D expenses was mainly due to higher clinical trial costs associated with the advancement of the company's clinical trials [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2509） 未經審核中期業績公告 董事會欣然公佈本集團截至2025年6月30日止六個月之未經審核簡明綜合業績，連 同截至2024年6月30日止六個月之未經審核比較數字。本集團於報告期內的未經審 核綜合財務報表已經本公司審核委員會及核數師審閱。 截 至2025年6月30日止六個月之 | 財務摘要 | | | | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | ...

格隆汇8月15日丨荃信生物-B(02509.HK)公布，为采纳高水准的企业管治，董事会已指定独立非执行董 事冯志伟先生自2025年8月15日起担任首席独立非执行董事一职。 ...

智通财经APP讯，荃信生物-B(02509)发布公告，为采纳高水准的企业管治，董事会已指定独立非执行董 事冯志伟先生自2025年8月15日起担任首席独立非执行董事一职。 ...